乳がんコアニードル生検市場規模、シェア、動向分析レポート：技術別、最終用途別、地域別、セグメント予測、2023年～2030年

乳がんコアニードル生検市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の乳がんコアニードル生検市場は2030年までに11億5,000万米ドルに達する見込みです。

同市場は2023年から2030年にかけてCAGR 4.9％で成長すると予測されています。市場成長の主な要因は、乳がんの有病率の増加、定期的なマンモグラフィ検診の推奨の普及、個人の意識の高まり、この分野で実施された広範な調査などです。これらの要因が総合的に乳がんコアニードル生検の需要増加と採用に寄与しており、今後数年間の著しい成長への道を開いています。

さらに、画像技術や生検技術の絶え間ない進歩も業界の拡大に寄与しています。早期発見と診断が患者の予後改善に果たす重要な役割に対する認識が高まっています。コアニードル生検は、従来の開腹手術による生検に比べ、侵襲性の低減、回復時間の短縮、費用対効果など、明確な利点があります。

早期発見・診断の需要が高まり続ける中、乳がんコアニードル生検市場は大きな成長が見込まれています。この分野における革新的な研究の最近の例としては、スペインのIMIM（Hospital del Mar Medical Research Institute）の研究者が2022年にEuropean Radiology誌に発表した調査結果のように、病変の可視化にMRI技術を利用した造影マンモグラフィ誘導乳房生検の使用が挙げられます。

COVID-19の大流行は、乳がんコアニードル生検市場における課題であると同時に新たな機会ももたらしました。必要のない処置の遅れは、診断率の低下とコアニードル生検の需要の減少につながった。しかし、パンデミックは早期発見の重要性を強調し、ヘルスケア提供者に検診と生検を優先させ、需要の復活をもたらしました。

乳がんコアニードル生検市場レポート・ハイライト

• 技術別では、超音波ベースの乳房生検分野が、疾患診断の点で他の生検技術より優れているため、2022年の市場を独占しました。さらに、技術進歩の増加も同分野の成長を加速すると予測されます。
• 最終用途別では、病院・診断研究所分野が2022年に最大の市場シェアを占めました。これは、病院における乳がん生検装置の採用が増加していることと、新しい診断技術への需要が高まっていることによる。
• 北米は、高度に発達したヘルスケアインフラと技術的に先進的な企業の存在により、2022年の同市場における地域別地位は高いです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

• 市場セグメンテーションと範囲
• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場動向と展望
• 市場促進要因
  • 乳がんの罹患率の増加
  • 画像技術と生検技術の進歩
  • 低侵襲手術への関心の高まり
• 市場の抑制
  • コアニードル生検処置の高額な費用
  • 限られた専門知識とトレーニング
• 業界分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19感染症の影響分析

第4章 技術ビジネス分析

• 乳がんコアニードル生検市場：技術変動分析
• MRIベースの乳房生検
  • MRIベースの乳房生検市場、2018年～2030年
• 超音波ベースの乳房生検
  • 超音波ベースの乳房生検市場、2018年～2030年
• マンモグラフィーベースの（定位的）乳房生検
  • マンモグラフィーベース
• CTベースの乳房生検
  • CTベースの乳房生検市場、2018年～2030年
• その他の画像ベースの乳房生検
  • その他の画像ベースの乳房生検市場、2018年～2030年

第5章 最終用途ビジネス分析

• 乳がんコアニードル生検市場：最終用途の変動分析
• 病院・検査機関
  • 病院・検査機関の市場、2018年～2030年
• 製薬・バイオテクノロジー企業
  • 製薬・バイオテクノロジー企業、市場、2018年～2030年
• 学術・研究機関
  • 学術・研究機関の市場、2018年～2030年

第6章 地域ビジネス分析

• 地域別乳がんコアニードル生検市場シェア、2022年および2030年
• 北米
  • SWOT分析
  • 北米の乳がんコアニードル生検、2018年～2030年
  • 米国
  • カナダ
• 欧州
  • SWOT分析
  • 欧州の乳がんコアニードル生検市場、2018年～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • SWOT分析
  • アジア太平洋の乳がんコアニードル生検、2018年～2030年
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • SWOT分析
  • ラテンアメリカの乳がんコアニードル生検、2018年～2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • SWOT分析
  • 中東・アフリカの乳がんコアニードル生検、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 企業の分類
• 戦略マッピング
• 企業の市場シェア分析、2022年
• 企業プロファイル・一覧表
  • Intact Medical Corporation.
  • Ethicon Surgical Technologies
  • Gallini SRL
  • Leica Biosystems Nussloch GmbH
  • Hologic, Inc.
  • Argon Medical Devices
  • Encapsule Medical Devices LLC
  • Cook Medical Incorporated
  • Becton, Dickinson and Company
  • CR Bard, Inc.

List of Tables

• Table 1 List of abbreviations
• Table 2 Global breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 3 Global breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 4 Global breast cancer core needle biopsy market, by region, 2018 - 2030 (USD Million)
• Table 5 North America breast cancer core needle biopsy market, by country, 2018 - 2030 (USD Million)
• Table 6 North America breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 7 North America breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 8 U.S. breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 9 U.S. breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 10 Canada breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 11 Canada breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 12 Europe breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
• Table 13 Europe breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 14 Europe breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 15 UK breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 16 UK breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 17 Germany breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 18 Germany breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 19 France breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 20 France breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 21 Italy breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 22 Italy breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 23 Spain breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 24 Spain breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 25 Denmark breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 26 Denmark breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 27 Sweden breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 28 Sweden breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 29 Norway breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 30 Norway breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 31 Asia Pacific breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
• Table 32 Asia Pacific breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 33 Asia Pacific breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 34 Japan breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 35 Japan breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 36 China breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 37 China breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 38 India breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 39 India breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 40 Australia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 41 Australia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 42 Thailand breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 43 Thailand breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 44 South Korea breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 45 South Korea breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 46 Latin America breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
• Table 47 Latin America breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 48 Latin America breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 49 Brazil breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 50 Brazil breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 51 Mexico breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 52 Mexico breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 53 Argentina breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 54 Argentina breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 55 Middle East & Africa breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa breast cancer core needle biopsy, by technology, 2018-2030, (USD
• Table 57 Middle East & Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 58 South Africa breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 59 South Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 60 Saudi Arabia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 62 UAE breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 63 UAE breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
• Table 64 Kuwait breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
• Table 65 Kuwait breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 breast cancer core needle biopsy market segmentation
• Fig. 8 Market snapshot, 2022
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 13 Porter's Five Forces analysis
• Fig. 14 Market penetration & growth prospect mapping, 2022
• Fig. 15 Global breast cancer core needle biopsy market: Technology movement analysis
• Fig. 16 Global breast cancer core needle biopsy market, for MRI-based breast biopsy, 2018 - 2030 (USD Million)
• Fig. 17 Global breast cancer core needle biopsy market, for ultrasound-based breast biopsy, 2018 - 2030 (USD Million)
• Fig. 18 Global breast cancer core needle biopsy market, for mammography-based (stereotactic) breast biopsy, 2018 - 2030 (USD Million)
• Fig. 19 Global breast cancer core needle biopsy market, for CT-based breast biopsy, 2018 - 2030 (USD Million)
• Fig. 20 Global breast cancer core needle biopsy market, for other image-based breast biopsy, 2018 - 2030 (USD Million)
• Fig. 21 Global breast cancer core needle biopsy market: End use movement analysis
• Fig. 22 Global breast cancer core needle biopsy market, for hospitals & diagnostic laboratories, 2018 - 2030 (USD Million)
• Fig. 23 Global breast cancer core needle biopsy market, for pharmaceutical & biotechnology companies, 2018 - 2030 (USD Million)
• Fig. 24 Global breast cancer core needle biopsy market, for academic & research institutes, 2018 - 2030 (USD Million)
• Fig. 25 Regional marketplace: Key takeaways
• Fig. 26 Regional outlook, 2022 & 2030
• Fig. 27 Global breast cancer core needle biopsy market: Region movement analysis
• Fig. 28 North America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 29 U.S. breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 30 Canada breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 31 Europe breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 32 Germany breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 33 UK breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 34 France breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 35 Italy breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 36 Spain breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 37 Denmark breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 38 Sweden breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 39 Norway breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 40 Asia Pacific breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 41 Japan breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 42 China breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 43 India breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 44 Australia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 45 South Korea breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 46 Thailand breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 47 Latin America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 48 Brazil breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 49 Mexico breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 50 Argentina breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 51 Middle East and Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 52 South Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 53 Saudi Arabia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 54 UAE breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
• Fig. 55 Kuwait breast cancer core needle biopsy market, 2018 - 2030 (USD Million)

Breast Cancer Core Needle Biopsy Market Growth & Trends:

The global breast cancer core needle biopsy market is expected to reach USD 1.15 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 4.9% from 2023 to 2030. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

Breast Cancer Core Needle Biopsy Market Report Highlights:

• By technology, the ultrasound-based breast biopsy segment dominated the market in 2022 due to its advantages over other biopsy technologies in terms of disease diagnosis. Further, increasing technological advancements are also expected to accelerate segment growth.
• By end-use, hospitals & diagnostic laboratories segment held the largest market share in 2022, due to the increasing adoption of breast cancer biopsy instruments in hospitals along with growing demand for novel diagnostics technologies.
• North America held a strong regional position in the market in 2022 owing to its highly developed healthcare infrastructure and presence of technologically advanced companies.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Technology Segment
    • 1.1.1.2. End Use
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
  • 1.4.1. Objective 1
  • 1.4.2. Objective 2
  • 1.4.3. Objective 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Drivers
  • 3.4.1. Growing prevalence of breast cancer
  • 3.4.2. Advancement in imaging technologies and biopsy techniques
  • 3.4.3. Rising inclination towards minimally invasive procedures
• 3.5. Market Restraint
  • 3.5.1. High cost of core needle biopsy procedures
  • 3.5.2. Limited expertise and training
• 3.6. Industry Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

• 4.1. Breast Cancer Core Needle Biopsy Market: Technology Movement Analysis
• 4.2. MRI-Based Breast Biopsy
  • 4.2.1. MRI-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
• 4.3. Fermentation Ultrasound-Based Breast Biopsy
  • 4.3.1. Ultrasound-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
• 4.4. Mammography-Based (Stereotactic) Breast Biopsy
  • 4.4.1. Mammography-Based (Stereotactic) Breast Biopsy Market, 2018 - 2030 (USD Million)
• 4.5. CT-Based Breast Biopsy
  • 4.5.1. CT-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
• 4.6. Other Image-Based Breast Biopsy
  • 4.6.1. Other Image-Based Breast Biopsy Market, 2018 - 2030 (USD Million)

Chapter 5. End-use Business Analysis

• 5.1. Breast Cancer Core Needle Biopsy Market: End-use Movement Analysis
• 5.2. Hospitals & Diagnostic Laboratories
  • 5.2.1. Hospitals & Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
• 5.3. Pharmaceutical & Biotechnology companies
  • 5.3.1. Pharmaceutical & Biotechnology Companies, Market, 2018 - 2030 (USD Million)
• 5.4. Academic & Research Institutes
  • 5.4.1. Academic And Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

• 6.1. Breast Cancer Core Needle Biopsy Market Share By Region, 2022 & 2030
• 6.2. North America
  • 6.2.1. SWOT Analysis
  • 6.2.2. North America Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.2.3. U.S.
    • 6.2.3.1. Key Country Dynamics
    • 6.2.3.2. Target Disease Prevalence
    • 6.2.3.3. Competitive Scenario
    • 6.2.3.4. Regulatory Framework
    • 6.2.3.5. U.S. Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.2.4. Canada
    • 6.2.4.1. Key Country Dynamics
    • 6.2.4.2. Target Disease Prevalence
    • 6.2.4.3. Competitive Scenario
    • 6.2.4.4. Regulatory Framework
    • 6.2.4.5. Canada Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
• 6.3. Europe
  • 6.3.1. SWOT Analysis
  • 6.3.2. Europe Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
  • 6.3.3. UK
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Target Disease Prevalence
    • 6.3.3.3. Competitive Scenario
    • 6.3.3.4. Regulatory Framework
    • 6.3.3.5. UK Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
  • 6.3.4. Germany
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Target Disease Prevalence
    • 6.3.4.3. Competitive Scenario
    • 6.3.4.4. Regulatory Framework
    • 6.3.4.5. Germany Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
  • 6.3.5. France
    • 6.3.5.1. Key Country Dynamics
    • 6.3.5.2. Target Disease Prevalence
    • 6.3.5.3. Competitive Scenario
    • 6.3.5.4. Regulatory Framework
    • 6.3.5.5. France Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.3.6. Italy
    • 6.3.6.1. Key Country Dynamics
    • 6.3.6.2. Target Disease Prevalence
    • 6.3.6.3. Competitive Scenario
    • 6.3.6.4. Regulatory Framework
    • 6.3.6.5. Italy Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.3.7. Spain
    • 6.3.7.1. Key Country Dynamics
    • 6.3.7.2. Target Disease Prevalence
    • 6.3.7.3. Competitive Scenario
    • 6.3.7.4. Regulatory Framework
    • 6.3.7.5. Spain Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.3.8. Denmark
    • 6.3.8.1. Key Country Dynamics
    • 6.3.8.2. Target Disease Prevalence
    • 6.3.8.3. Competitive Scenario
    • 6.3.8.4. Regulatory Framework
    • 6.3.8.5. Denmark Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.3.9. Sweden
    • 6.3.9.1. Key Country Dynamics
    • 6.3.9.2. Target Disease Prevalence
    • 6.3.9.3. Competitive Scenario
    • 6.3.9.4. Regulatory Framework
    • 6.3.9.5. Sweden Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.3.10. Norway
    • 6.3.10.1. Key Country Dynamics
    • 6.3.10.2. Target Disease Prevalence
    • 6.3.10.3. Competitive Scenario
    • 6.3.10.4. Regulatory Framework
    • 6.3.10.5. Norway Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. SWOT Analysis
  • 6.4.2. Asia Pacific Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.4.3. Japan
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Regulatory Framework
    • 6.4.3.5. Japan Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.4.4. China
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Competitive Scenario
    • 6.4.4.4. Regulatory Framework
    • 6.4.4.5. China Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.4.5. India
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Target Disease Prevalence
    • 6.4.5.3. Competitive Scenario
    • 6.4.5.4. Regulatory Framework
    • 6.4.5.5. India Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.4.6. Australia
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Target Disease Prevalence
    • 6.4.6.3. Competitive Scenario
    • 6.4.6.4. Regulatory Framework
    • 6.4.6.5. Australia Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.4.7. Thailand
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Target Disease Prevalence
    • 6.4.7.3. Competitive Scenario
    • 6.4.7.4. Regulatory Framework
    • 6.4.7.5. Thailand Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.4.8. South Korea
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Target Disease Prevalence
    • 6.4.8.3. Competitive Scenario
    • 6.4.8.4. Regulatory Framework
    • 6.4.8.5. South Korea Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
• 6.5. Latin America
  • 6.5.1. SWOT Analysis
  • 6.5.2. Latin America Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.5.3. Brazil
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. Regulatory Framework
    • 6.5.3.5. Brazil Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Regulatory Framework
    • 6.5.4.5. Mexico Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.5.5. Argentina
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Regulatory Framework
    • 6.5.5.5. Argentina Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
• 6.6. MEA
  • 6.6.1. SWOT Analysis
  • 6.6.2. MEA Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.6.3. South Africa
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. Regulatory Framework
    • 6.6.3.5. South Africa Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.6.4. Saudi Arabia
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. Regulatory Framework
    • 6.6.4.5. Saudi Arabia Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.6.5. UAE
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Regulatory Framework
    • 6.6.5.5. UAE Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.6.6. Kuwait
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Regulatory Framework
    • 6.6.6.5. Kuwait Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Share Analysis, 2022
• 7.4. Company Profiles/Listing
  • 7.4.1. Intact Medical Corporation.
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Ethicon Surgical Technologies
    • 7.4.2.1. Overview
    • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Gallini SRL
    • 7.4.3.1. Overview
    • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Leica Biosystems Nussloch GmbH
    • 7.4.4.1. Overview
    • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Hologic, Inc.
    • 7.4.5.1. Overview
    • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Argon Medical Devices
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Encapsule Medical Devices LLC
    • 7.4.7.1. Overview
    • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Cook Medical Incorporated
    • 7.4.8.1. Overview
    • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Becton, Dickinson and Company
    • 7.4.9.1. Overview
    • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. C.R. Bard, Inc.
    • 7.4.10.1. Overview
    • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives